PMH12 THE COST OF RELAPSES MANAGEMENT IN PATIENTS SUFFERING FROM SCHIZOPHRENIA IN ITALY AND SPAIN: COMPARISON BETWEEN LURASIDONE AND QUETIAPINE XR

Autor:	P. Mierzejewski, Manuel García-Goñi, B. Crespo Facorro, M. Lew-Starowicz, Davide Croce, Umberto Restelli, P. Rocca, Sofia Silvola
Rok vydání:	2019
Předmět:	medicine.medical_specialty Schizophrenia business.industry Health Policy Public Health Environmental and Occupational Health medicine Quetiapine In patient medicine.disease Psychiatry business medicine.drug Lurasidone
Zdroj:	Value in Health. 22:S682
ISSN:	1098-3015
DOI:	10.1016/j.jval.2019.09.1486
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::6b769dee06b366ed20b378338950a90d https://doi.org/10.1016/j.jval.2019.09.1486 Zobrazit plný text záznamu Full Text from ScienceDirect